
Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal
Regulus Therapeutics just finished dosing in IND-enabling toxicity studies for its second-generation autosomal dominant polycystic kidney disease (ADPKD) candidate RGLS8429.
Based on FDA discussions and data from a Phase Ib trial on original ADPKD candidate RGLS4326, Regulus is shifting away from the first-generation candidate and prioritizing the newer candidate, according to a statement.
“We have determined that advancing our next-generation compound RGLS8429 is more compelling than further development of RGLS4326,” said Regulus CEO Jay Hagan. “The extensive work and investment we have made in RGLS4326 will directly inform the advancement of RGLS8429, and we believe will make this transition both expeditious and productive.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.